Nicotinamide Mononucleotide

Clinical Summary

NMN is a nucleotide precursor to NAD (nicotinamide adenine dinucleotide) in the salvage pathway. NAD+ declines 30-50% by age 50-60 due to reduced NAMPT enzyme activity, impairing mitochondrial function, DNA repair, sirtuin signaling, and circadian rhythm regulation.

Oral NMN at 250-900 mg/day reliably elevates blood NAD+ levels (38-51% increase, p<0.001) across multiple RCTs. The optimal dose appears to be 600 mg/day based on dose-response data — 900 mg provides no additional benefit for most endpoints. Clinical outcomes include modest improvements in physical performance (6-minute walk test), muscle insulin sensitivity in prediabetic women, and sleep quality in older adults. A 2026 Nature Metabolism head-to-head comparison revealed that oral NMN is primarily converted to nicotinic acid by gut microbiota before reaching NAD+ via the Preiss-Handler pathway — not directly absorbed as intact NMN (PMID: 41540253). This fundamentally changes the mechanistic narrative.

The most comprehensive systematic review to date (113 studies, 2026) concluded that NMN consistently demonstrates biochemical target engagement (NAD+ elevation) and good tolerability, but effects on functional, metabolic, and vascular outcomes remain "heterogeneous and often null" (PMID: 41655607). A meta-analysis for sarcopenia endpoints found no significant effects on muscle mass, grip strength, or gait speed (PMID: 40275690). Cancer interaction is double-edged: NMN protects against colorectal tumorigenesis but vitamin B3 derivatives may support pancreatic cancer cell survival. The first mammalian lifespan study showed NMN extended female mouse lifespan by 8.5% but had no effect on male lifespan (PMID: 38979132).

Safety profile is excellent across all human trials (up to 1200 mg/day, 12 weeks). FAERS data shows zero suspect-drug reports — NMN appears only as concomitant medication in the database. No serious adverse events documented.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend:

Prescribing

Dosing Table

Formulation Table

Note on absorption mechanism: 2025-2026 research (Yaku, Science Advances; Christen, Nature Metabolism) demonstrates oral NMN is primarily deamidated by gut microbiota to nicotinic acid, then reaches NAD+ via the Preiss-Handler pathway. Direct intact absorption via Slc12a8 transporter is minimal. This means gut microbiome health directly affects NMN efficacy.

Cycling: NOT recommended. NAD+ decline is continuous; no tolerance/desensitization documented in trials up to 12 months. Daily continuous use is appropriate.

Condition-Specific Protocols

Prediabetes / Insulin Resistance Protocol

Evidence: 4/5 | PMID: 33888596

Phase 1: Initiation (Weeks 1-4)

• 250 mg/d oral β-NMN, morning, empty stomach
• Baseline labs: fasting glucose, HbA1c, fasting insulin, HOMA-IR
• If on insulin/sulfonylureas: monitor glucose daily for first 2 weeks; risk of hypoglycemia

Phase 2: Therapeutic (Weeks 5-12)

• Continue 250 mg/d (the effective dose from the landmark RCT)
• Fasting glucose every 2 weeks
• HbA1c at week 12

Phase 3: Maintenance (Week 12+)

• Continue 250 mg/d long-term
• HbA1c every 3 months
• Reassess HOMA-IR at 6 months

Drug Interaction Timing: If on metformin, take together (additive insulin-sensitizing effects). If on insulin/sulfonylureas, may need 10-25% dose reduction. Expected Outcomes: 25% improvement in muscle insulin sensitivity by week 10. No expected change in body weight, liver fat, or lipid profile. Stop/Reassess Criteria: Hypoglycemia episodes; no HbA1c improvement after 6 months; active cancer diagnosis.

Physical Performance Protocol (Middle-Aged/Elderly)

Evidence: 4/5 | PMID: 36482258

Phase 1: Initiation (Weeks 1-2)

• 300 mg/d oral β-NMN, morning
• Baseline: 6-minute walk test, SF-36

Phase 2: Therapeutic (Weeks 3-8)

• Increase to 600 mg/d
• Combine with regular exercise (walking, moderate aerobic) for synergistic benefit
• Reassess walking distance at week 4

Phase 3: Maintenance (Week 8+)

• Continue 600 mg/d (900 mg provides no additional benefit)
• 6-minute walk test every 3 months
• SF-36 quality of life assessment every 6 months

Expected Outcomes: +50-80m on 6-minute walk test (8-12% improvement) by week 8. SF-36 improvement across physical function and vitality domains. Stop/Reassess Criteria: No subjective or objective improvement after 12 weeks; budget constraints (consider switching to NR or lower dose).

Safety

Interactions Table

Contraindications

Absolute:

• Active cancer undergoing chemotherapy/radiation (NAD+ may support tumor growth; PMID: 41724424)
• Known hypersensitivity to NMN or nicotinamide compounds

Relative:

• Pregnancy/lactation (no safety data)
• Children <18 (unnecessary; high endogenous NAD+)
• Advanced kidney disease eGFR <30 (unknown excretion)
• Cancer history within 5 years (oncology consultation advised)
• Severe hepatic impairment Child-Pugh C (unpredictable NAD+ metabolism)

Adverse Effects

Common (>1%): None consistently reported across trials. Remarkably well-tolerated.

Uncommon (0.1-1%):

• Mild GI upset (nausea, bloating) at >900 mg — reported in <5% of trial participants
• Mild headache (rare, typically first week)
• Increased energy/alertness — may disrupt sleep if taken in evening

Rare (<0.1%): No serious adverse events in any published human trial (up to 1200 mg/d, 12 weeks).

Exercise-specific caution (NEW): A 2026 RCT (PMID: 41705654) found NMN 1200 mg/d suppressed exercise-induced mitochondrial content increase by abolishing mitochondrial transfer from phagocytes during muscle repair, despite anti-inflammatory effects. Implications: NMN may blunt exercise adaptations at high doses. Consider lower doses (300-600 mg) for athletes or timing away from intense training.

FAERS Signal Table

Interpretation: FAERS data for NMN is uninformative. In ALL reports, NMN appears as concomitant medication — never the suspect drug. Total ~11 reports across all reactions. This is typical for supplements not in FDA's drug database. Zero clinically meaningful safety signals.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Synergies & Stacking

Antagonistic:

• Chronic alcohol: depletes NAD+ via ALDH, directly counteracts NMN
• High-dose niacin (>1000 mg): redundant pathways; no benefit from combining

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No known pharmacogenomic modifiers with direct clinical testing recommendations for NMN at this time. The gut microbiome emerges as the most important "genetic" modifier — variable microbial composition likely explains the high inter-individual variability in NMN response.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-to-cautiously-positive across ~500-1000+ reports. Community is split: ~30-40% report clear subjective benefits, ~30-40% report "felt nothing," and ~20-30% report subtle improvements.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: CalerieHealth SOD+NMN product uses MLM/direct-selling. Major NMN brands are not MLM.
• Influencer concentration: David Sinclair (Harvard) is the primary NMN evangelist. Co-founded Metro International Biotech (MIB-626 drug candidate). Commercial conflict acknowledged. His rival Charles Brenner (ChromaDex/NR) has equally entangled commercial interests. Both sides have financial incentives.
• Astroturfing signals: >50% of Amazon NMN products tested contained little to no actual NMN. Fake Certificates of Analysis circulate. Many "best NMN" review sites are affiliate content farms (charava.co.uk, omre.co, brainflow.co).
• Commercial bias: Positive reviews strongly correlated with affiliate links. YouTube NMN content is heavily monetized.
• Researcher-flagged exaggeration: A 2024 meta-analysis explicitly stated "an exaggeration of the benefits of NMN supplementation may exist in the field."

Folk vs Clinical Reality Check

Community experience ALIGNS with clinical data on: energy improvements (modest but real), sleep quality (especially AM dosing), and exercise endurance. Community DIVERGES on: weight loss (clinical data shows zero effect), dramatic anti-aging claims (grey hair reversal has zero clinical evidence), and perceived dose needs (community doses higher than RCT-optimal 600 mg). The ~30-40% "felt nothing" rate likely reflects a combination of product fraud (>50% of Amazon products are fake/underdosed), genuine non-responders, and the subtle, gradual nature of NMN's effects which don't produce an acute "feeling." The community dramatically underappreciates the only well-supported clinical signal (muscle insulin sensitivity in prediabetic populations) while overemphasizing subjective energy effects.

Deep Dive: Mechanisms & Research

Key Mechanisms (with Clinical Translation Status)

NAD+ Salvage Pathway Restoration: Nicotinamide → NMN (via NAMPT, rate-limiting) → NAD (via NMNATs). NAMPT activity declines with age. NMN supplementation bypasses the NAMPT bottleneck. Translation: YES — multiple RCTs confirm blood NAD+ elevation in humans.

Gut Microbiota-Mediated Absorption (2025-2026 paradigm shift): Oral NMN is primarily deamidated by gut bacteria to nicotinic acid (NA), which enters NAD+ via the Preiss-Handler pathway. Direct absorption via Slc12a8 transporter is minimal. IV NMN is also rapidly degraded to nicotinamide, then deamidated by gut bacteria. This means gut health directly impacts NMN efficacy (PMID: 40117359, 41540253). Translation: PARTIAL — mechanism confirmed in humans; clinical implications of microbiome variation not yet quantified.

Sirtuin Activation: NAD+ is a required substrate for SIRT1-7 deacetylases. SIRT1 improves insulin sensitivity, enhances mitochondrial biogenesis, and modulates circadian rhythms. NMN elevates NAD+ → activates sirtuins. Translation: PARTIAL — insulin sensitivity improvement confirmed; lifespan extension in humans unproven.

DNA Repair (PARP): PARPs consume NAD+ for DNA damage repair. Chronic NAD+ depletion impairs repair capacity. NMN restores PARP activity in aged cells. Translation: NO — no human clinical endpoints for DNA repair demonstrated yet.

Circadian NAD+ Oscillation: NAD+ levels oscillate with circadian rhythm. Age-related NAD+ decline disrupts this oscillation. NMN may restore circadian NAD+ cycling. Translation: PARTIAL — sleep quality improvements in Japanese RCTs are consistent but not definitive.

Clinical Trials (from ClinicalTrials.gov + East Asian Registries)

Regulatory Status

• FDA (US): September 2025 — FDA reversed its November 2022 exclusion and declared NMN lawful for use in dietary supplements. December 2025 — FDA reinstated NDI status. NMN may now be marketed as a dietary supplement. MIB-626 (pharmaceutical-grade NMN by Metro International Biotech) remains in Phase 2 drug development.
• EMA (EU): No drug approval. EFSA initiated formal safety evaluation as Novel Food (July 2025, pending).
• WADA: NOT on the Prohibited List (as of 2026).
• Japan: Marketed as food/supplement. Multiple clinical studies under JPRN/UMIN.
• China: Widely sold as supplement. Multiple ChiCTR-registered trials.
• Regulatory context: The 2022 FDA exclusion was driven by Metro International Biotech's IND filing (attempting drug classification for commercial monopoly — a cui bono play). NPA lawsuit and citizen petitions forced reversal. NMN's supplement status was restored for commercial/legal reasons, not because new safety data emerged.

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Hasty generalization (animal → human): HIGH confidence. Multiple sections of older NMN literature extrapolate mouse doses (500 mg/kg) to human recommendations without allometric scaling. Cognitive, vascular, and fertility claims rest entirely on rodent models.
• Surrogate endpoint inflation: MEDIUM confidence. Blood NAD+ elevation is consistently presented as a health benefit itself, but it is a biomarker — not a clinical outcome. The antioxidant supplement precedent (vitamin E, beta-carotene raised biomarkers but failed on clinical endpoints) applies here.
• Appeal to authority: MEDIUM confidence. David Sinclair's influence permeates the NMN field. Das et al. 2018 (from his lab) is the cornerstone vascular study. His personal NMN use is widely cited as evidence. One researcher's practice ≠ clinical evidence.
• Cherry-picking: LOW-MEDIUM. The NMN literature generally acknowledges negative findings (no weight loss, cancer concerns), but the community ecosystem heavily amplifies positives.

Evidence Gaps

• Long-term safety beyond 12 weeks in humans (no trials >12 weeks published)
• Tissue-specific NAD+ elevation (brain, muscle, liver) in humans — blood ≠ tissue
• Head-to-head NMN vs NR clinical outcomes (the 2026 Nature Metabolism study showed comparable NAD+ elevation but no functional outcome comparison)
• Cognitive function RCTs in humans (zero published despite strong animal data)
• Cancer outcomes at any timeline (theoretical concern unresolved in either direction)
• Male-specific RCTs for insulin sensitivity (Yoshino enrolled only women)
• Dose optimization for specific populations (athletes, elderly >75, renal impairment)
• Gut microbiome variation as a modifier of NMN efficacy (newly recognized critical gap)

Bias Flags (Mode 4: First Principles)

Core unexamined assumption: "Blood NAD+ elevation = tissue NAD+ elevation = health benefit." This three-step logical chain is the foundation of the entire NMN thesis. Step 1 is proven (RCTs confirm blood NAD+ rises). Steps 2 and 3 are assumed, not proven. The 2025-2026 mechanistic data showing gut-mediated conversion actually makes tissue distribution LESS certain, not more.

Second assumption: "Age-related NAD+ decline causes disease." NAMPT decline is documented, but directionality is not established. NAD+ decline could be a consequence of aging processes, not a cause. Correcting the biomarker may not correct the disease.

Third assumption: "NMN is superior to cheaper niacin/nicotinamide." The 2026 Nature Metabolism head-to-head showed comparable NAD+ elevation across NMN, NR, and nicotinamide. If all three reach NAD+ via gut conversion to nicotinic acid anyway, the premium for NMN ($50/mo vs $5/mo for niacin) may not be justified.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: The NMN supplement industry ($500M+ market) benefits from anti-aging urgency narratives. "NAD+ decline" pathologizes normal aging. Premium pricing ($50-80/mo) is positioned as accessible investment in longevity.
• Influencer economics: David Sinclair (Harvard) co-founded Metro International Biotech (MIB-626). His book "Lifespan" drove consumer NMN demand. Bryan Johnson's Blueprint Protocol includes NAD+ precursors within a 100+ supplement regimen (impossible to isolate NMN effect). Affiliate marketing is pervasive.
• Counter-narrative manipulation: Charles Brenner (ChromaDex/NR) has financial interests in discrediting NMN in favor of NR. The NMN vs NR debate is partly a commercial rivalry, not purely scientific.
• Cui bono summary: Pro-NMN: supplement companies, longevity influencers (affiliate revenue). Anti-NMN: Metro International Biotech (drug monopoly attempt, reversed 2025), ChromaDex (NR competitor). Neutral: academic researchers (funded by both sides).
• Red team highlight: The most concerning angle is historical precedent — antioxidant supplements (vitamin E, beta-carotene, selenium) had equally strong mechanistic rationale, raised biomarkers beautifully, and then FAILED or HARMED in large long-term RCTs. NMN has not yet had its "ATBC trial moment." The absence of long-term outcome data is not evidence of safety; it is an absence of evidence.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 6/10 — strong mechanistic rationale for NAD+ restoration in metabolic, cognitive, and longevity domains; growing but still limited human outcome data and cheaper precursors (niacin, NAM) may match elevation per 2026 Nature Metabolism evidence.
• Opportunity cost: $50-70/month; daily pill burden; potential cancer uncertainty for those with history; the same money could fund $5/mo of niacin (which may achieve comparable NAD+ elevation per 2026 Nature Metabolism data).
• Verdict: CONDITIONAL
• Conditions: (1) Age >40 with interest in NAD+ restoration; (2) Not in active cancer treatment or within 5 years of cancer diagnosis; (3) Budget allows without displacing higher-evidence interventions (exercise, sleep, diet); (4) Sourced from third-party tested brands with valid CoA (NOT Amazon marketplace).

Bottom Line

NMN reliably raises blood NAD+ and modestly improves physical performance and insulin sensitivity. It is remarkably safe in short-term studies. But the gap between biochemical target engagement (proven) and meaningful clinical outcomes (modest, sometimes null) is the central unresolved question. The 2026 gut microbiota mechanism studies challenge the direct-absorption narrative and raise the uncomfortable question of whether cheap niacin achieves the same thing. For a healthy person over 40 with disposable income and realistic expectations, NMN is a reasonable bet on accumulating evidence. For someone seeking dramatic anti-aging effects, the evidence does not support that expectation. Exercise remains a more powerful and better-proven NAD+ intervention than any supplement.

Practical Notes

Brands & Product Selection

Third-party testing is CRITICAL. >50% of Amazon NMN products contain little to no actual NMN.

Quality markers:

• Certificate of Analysis (CoA) from independent lab (not manufacturer's own)
• Purity >99% β-NMN confirmed by HPLC
• Heavy metals <5 ppm; microbial contamination negative
• Batch/lot number on bottle
• GMP-certified facility

Reputable brands (not endorsements):

• ProHealth Longevity (Uthever NMN; third-party tested; CoA available)
• DoNotAge (>99% purity; European; CoA on website)
• Life Extension (established company; third-party verified)
• Alive By Science (multiple forms; independent testing)

Red flags:

• Price <$30/month for 600 mg dose (likely degraded or fake)
• No CoA on request; "proprietary blend" hiding NMN amount
• Sold exclusively via MLM
• No batch/lot number
• Amazon marketplace listings without brand verification

Storage & Handling

• Temperature: 15-25°C; avoid heat >30°C
• Humidity: CRITICAL — NMN is highly hygroscopic. Use desiccant packets. Keep bottle sealed. Avoid bathroom storage.
• Light: Protect from direct sunlight; store in opaque container
• Shelf life: 18-24 months properly stored; refrigeration extends to 24-36 months
• Degradation indicator: Pure NMN is white to off-white. Yellowing = degraded. Clumping = moisture exposure.

Palatability & Compliance

• β-NMN powder is slightly bitter with mild metallic aftertaste
• Dissolves in water, juice, coffee, tea (stable in neutral pH)
• Capsules eliminate taste (recommended for most users)
• Once-daily dosing maximizes compliance — all RCTs used once-daily

Exercise & Circadian Timing

• Morning (6-9 AM): Aligns with circadian NAD+ peaks. Recommended for most users.
• Pre-workout (30-60 min): May enhance endurance performance. BUT: at >900 mg, may suppress post-exercise mitochondrial adaptation (PMID: 41705654). Use 300-600 mg for athletes.
• Evening: Avoid — some users report insomnia/alertness. Exception: Japanese studies found evening dosing improved sleep in elderly (PMID: 38789831) — timing may be population-dependent.
• Post-exercise: Not specifically studied. Theoretical recovery support.

Reference Ranges (Expected Biomarker Changes)

Cost

Cost-effectiveness note: The 2026 Nature Metabolism head-to-head (PMID: 41540253) showed NMN, NR, and nicotinamide all reach NAD+ via gut conversion to nicotinic acid. If the endpoint is blood NAD+ elevation, niacin at $5/month may be comparably effective to NMN at $48/month. However, NMN has more clinical outcome data (physical performance, insulin sensitivity) that niacin lacks. The premium buys clinical validation, not necessarily superior biochemistry.

What We Don't Know

• Whether blood NAD+ elevation translates to tissue NAD+ elevation in brain, muscle, and liver in humans
• Long-term safety beyond 12 weeks (no published human trials longer than this)
• Whether NMN is meaningfully superior to cheap niacin for clinical outcomes (not just NAD+ levels)
• Cancer interaction: does NAD+ elevation protect against cancer (DNA repair) or accelerate it (tumor metabolism)?
• Optimal dose for specific conditions (current 600 mg recommendation is from one dose-response study)
• Whether gut microbiome composition determines NMN responders vs non-responders
• Why NMN extends female but not male mouse lifespan — and whether this translates to humans
• Cognitive outcomes in humans (zero RCTs despite strong animal data)
• Whether the ~30-40% "non-responders" in community reports reflect product fraud, microbiome variation, or genuine biological non-response
• Whether NMN blunts exercise adaptations at high doses in trained athletes (one concerning RCT)
• Fertility outcomes in humans (IVF trials ongoing, no published results)
• Whether the "Sinclair protocol" (NMN + resveratrol) is better than NMN alone in humans (never tested)
• Appropriate use window: is there an age below which supplementation is unnecessary? Above which it is ineffective?

References

Systematic Reviews & Meta-Analyses

1. Gallagher R, Emmanuel J. (2026). NAD+ Precursors NR and NMN: Comprehensive PRISMA Systematic Review. Ageing Res Rev. PMID: 41655607 — Most comprehensive review to date (113 studies); concludes functional outcomes "heterogeneous and often null"
2. Zhang M, Chen Y, Jiang N, et al. (2026). NMN Supplementation on Blood Pressure: Systematic Review and Meta-Analysis. Nutrients. PMID: 41901064 — Blood pressure meta-analysis of RCTs
3. Prokopidis K, et al. (2025). NMN and NR on Skeletal Muscle Mass and Function: Systematic Review and Meta-Analysis. J Cachexia Sarcopenia Muscle. PMID: 40275690 — NO significant effects on muscle mass, grip strength, or gait speed
4. Wang JP, et al. (2025). NMN on Muscle and Liver Functions in Middle-Aged/Elderly: Systematic Review and Meta-Analysis. Curr Pharm Biotechnol. PMID: 39185644
5. Zhang J, Poon ET, Wong SH. (2025). Oral NMN on Glucose and Lipid Metabolism: Systematic Review with Meta-Analysis. Crit Rev Food Sci Nutr. PMID: 39116016
6. Chen F, et al. (2024). NMN on Glucose and Lipid Metabolism in Adults: Systematic Review and Meta-Analysis. Curr Diab Rep. PMID: 39531138
7. Wen X, et al. (2024). NMN Effects: Systematic Review of 10 RCTs (N=437). Cureus. PMID: 39221308
8. Noh H, et al. (2026). NMN for Oocyte Quality: Systematic Review and Transcriptomic Analysis. J Assist Reprod Genet. PMID: 41160202
9. Song Q, et al. (2023). Safety and Antiaging Effects of NMN in Human Clinical Trials: Update. Adv Nutr. PMID: 37619764
10. Nadeeshani H, et al. (2021). NMN as Anti-Aging Product: Promises and Safety Concerns. J Adv Res. PMID: 35499054

Landmark Human RCTs

11. Yi L, et al. (2022). β-NMN Supplementation in Healthy Middle-Aged Adults: Dose-Dependent RCT. Geroscience. PMID: 36482258 — N=80, 300/600/900mg, 60 days; dose-dependent NAD+ elevation; 600-900mg optimal for physical performance
12. Yoshino M, et al. (2021). NMN Increases Muscle Insulin Sensitivity in Prediabetic Women. Science. PMID: 33888596 — N=25, 250mg, 10 weeks; gold-standard clamp; 25% insulin sensitivity improvement
13. Morifuji M, et al. (2024). β-NMN: Blood NAD, Walking Speed, Sleep Quality in Older Adults. Geroscience. PMID: 38789831 — N=60, 250mg, 12 weeks; Japanese elderly; improved sleep + maintained walking speed
14. Yamaguchi S, et al. (2024). Long-Term NMN Safety in Healthy Middle-Aged Japanese Men. Endocr J. PMID: 38191197 — Long-term safety confirmed; metabolism + sleep improvements
15. Christen S, et al. (2026). Differential Impact of Three NAD+ Boosters on Circulatory NAD and Microbial Metabolism. Nat Metab. PMID: 41540253 — NMN vs NR vs nicotinamide head-to-head; all converted to NA via gut microbiota
16. Yang DL, et al. (2026). Anti-Inflammatory Effects of NMN in Human Skeletal Muscle After BFR-Exercise. J Int Soc Sports Nutr. PMID: 41705654 — N=11; NMN suppressed post-exercise mitochondrial content increase (cautionary)
17. Kuerec AH, et al. (2024). Personalized NMN Supplementation: NAD Concentration. Mech Ageing Dev. PMID: 38430946 — Individual variation in NAD+ response
18. Kuerec AH, et al. (2025). NMN-Induced NAD+ and Hemoglobin/Oxygen Capacity. Geroscience. PMID: 41162813 — Post-hoc analysis; NMN associated with enhanced oxygen-carrying capacity

Key Mechanistic Studies

19. Yaku K, et al. (2025). Oral NMN Gut Microbiota-Mediated Deamidation to NA. Science Advances. PMID: 40117359 — Paradigm shift: NMN primarily reaches NAD+ via gut bacteria conversion, not direct absorption
20. Das A, et al. (2018). Endothelial NAD+-H2S Signaling Network in Vascular Aging. Cell. PMID: 29570999 — NMN improved blood flow +56-80% endurance in aged mice
21. Zhan R, et al. (2023). NAD+ Rescues Age-Related BBB Damage via CX43-PARP1 Axis. Neuron. PMID: 37683629 — BBB repair in aged mice
22. Kane AE, Sinclair DA, et al. (2024). NMN Female Lifespan Extension Study. bioRxiv. PMID: 38979132 — +8.5% female median lifespan; no male effect; sex-specific NAD+ metabolism
23. Rajman L, Chwalek K, Sinclair DA. (2018). Therapeutic Potential of NAD-Boosting Molecules. Cell Metab. PMID: 29514064 — Comprehensive NAD+ biology review
24. Campbell JM. (2022). NAD+ Precursors to Prevent Cognitive Decline. Nutrients. PMID: 35956406
25. Sharma A, et al. (2023). NAD+ Synergistic Supplementation for Healthspan. Nutrients. PMID: 36678315

Reproductive / Fertility Studies

26. Bertoldo MJ, et al. (2020). NAD+ Repletion Rescues Female Fertility. Cell Rep. PMID: 32049001 — Oocyte quality restored in aged mice
27. Miao Y, et al. (2020). NMN Reverses Declining Oocyte Quality. Cell Rep. PMID: 32755581
28. Liang J, et al. (2024). NMN Rescues Mitochondrial Function in Aging Ovaries. MedComm. PMID: 39355508
29. Ho WJ, et al. (2024). Fertility Protection During Chemotherapy via NAD+ Boosting. EMBO Mol Med. PMID: 39169162
30. Fan Y, et al. (2025). NMN Reverses Declining Oocyte Quality in PCOS. FASEB J. PMID: 40678956
31. Ma L, et al. (2024). NMN Improves POI via NLRP3 Pyroptosis Inhibition. J Ovarian Res. PMID: 39593096

Neuroprotection Studies

32. Wang X, et al. (2016). NMN Protects Against β-Amyloid Cognitive Impairment. Brain Res. PMID: 27130898
33. Yoo KH, et al. (2021). NMN Prevents Cisplatin-Induced Cognitive Impairment. Cancer Res. PMID: 33771896
34. Hosseini L, et al. (2019). NMN + Melatonin Alleviate Aging Cognitive Impairment. Neuroscience. PMID: 31678348
35. Chandrasekaran K, et al. (2020). NMN Prevents Diabetes-Induced Cognitive Impairment. Int J Mol Sci. PMID: 32466541
36. Zhu X, et al. (2023). NMN Alleviates Neurological Impairment in TBI. Int J Med Sci. PMID: 36860678
37. Cheng Y, et al. (2024). NMN Alleviates Seizures via SIRT1-PGC-1α. J Neurochem. PMID: 38194959
38. Alghamdi M, Braidy N. (2024). NAD+ Precursors for Alzheimer's. J Alzheimers Dis. PMID: 39422945

Cancer / Safety Studies

39. Nakazzi F, et al. (2026). Vitamin B3 Derivatives Support Pancreatic Cancer Cell Survival. Cancer Lett. PMID: 41724424 — CAUTIONARY: NAD+ pathway supports pancreatic cancer
40. Li T, et al. (2024). NMN Protects STAT1 to Prevent Colorectal Tumorigenesis. MedComm. PMID: 39575303 — PROTECTIVE against colorectal cancer
41. Pihl C, et al. (2025). Oral NMN Increases Tissue NAD+ but Does NOT Protect Against UV Skin Cancer. Photochem Photobiol Sci. PMID: 40439965 — Important negative finding

Gut Microbiome / Digestive Studies

42. Tang Y, et al. (2024). NMN Fermentation in Gut: Prebiotic Effects. Food Res Int. PMID: 38225109 — +88% propionate, +23% butyrate
43. Zhou R, et al. (2026). NMN Modulates Gut Microbiota to Mitigate Alzheimer's. J Alzheimers Dis. PMID: 41805251
44. Shi Q, et al. (2025). TRF + NMN Improves Exercise via Gut Microbiota. Nutrients. PMID: 40362776

Cardiovascular / Organ Protection

45. Kiesworo K, et al. (2025). NMN Restores Endothelial Proliferation and Angiogenesis. iScience. PMID: 39868046
46. Wang X, et al. (2024). NMN Ameliorates Beta-Cell Dysfunction. Int J Mol Sci. PMID: 39408861

Skin / Anti-Aging

47. Sun Y, et al. (2025). NMN-Loaded EVs Delay Skin Aging via SIRT3 Mitophagy. Stem Cell Res Ther. PMID: 40598314

Comparative Studies

48. Palmer RD, et al. (2021). NAD+ Precursor Comparisons for Better Aging. Aging Med. PMID: 34553119
49. Qiu S, et al. (2024). NMN vs NR for DNA Damage Protection. Biochem Biophys Rep. PMID: 38333051

Additional

50. Fujita H, et al. (2024). NAD+ Metabolites in Cancer Patients Undergoing Surgery. Sci Rep. PMID: 39019993
51. Benjamin DJ, Crews FT. (2024). NMN Metabolic Variability and Clinical Implications. Metabolites. PMID: 38921475